STOCK TITAN

Cresco Labs Closes Acquisition of Three High-Performing Pennsylvania Dispensaries

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

Cresco Labs (OTCQX:CRLBF) announced the closing of its acquisition of Cure Pennsylvania, which includes three operational dispensaries located in Lancaster, Phoenixville, and Philadelphia. This acquisition expands Cresco's reach in Pennsylvania, complementing its existing Sunnyside dispensaries. The company anticipates enhancing operational efficiency through its retail model, aiming to increase revenues. CEO Charlie Bachtell stated that the move positions Cresco for future growth as it prepares for potential adult-use cannabis legalization in the state.

Positive
  • Acquisition of three high-performing dispensaries in Pennsylvania enhances market presence.
  • Cresco's retail model expected to improve revenue performance of newly acquired stores.
  • Strategic positioning for future growth in anticipation of adult-use legalization.
Negative
  • None.

CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the closing of the Company’s previously announced acquisition of Bay, LLC d/b/a Cure Pennsylvania (“Cure Penn” or the “Transaction”).

Cresco Labs closes acquisition of three Cure Penn dispensaries in Pennsylvania (Photo: Business Wire)

Cresco Labs closes acquisition of three Cure Penn dispensaries in Pennsylvania (Photo: Business Wire)

Transaction Highlights

  • Three operational dispensaries in Lancaster, Phoenixville, and Philadelphia
  • Cure Penn’s dispensary locations are incremental and complementary to Cresco Labs’ five existing Sunnyside dispensaries in Pennsylvania
  • A retail platform that outperforms the average revenues per-store in Pennsylvania, to be further improved through Cresco Labs’ Sunnyside* retail model

“Our focus heading into 2022 is on tailoring our strategy to the dynamics of each state to maintain a dominant market position and increase profitability. Between the acquisition of Cure Penn and the pending acquisition of Laurel Harvest, we are adding four new operational stores, licenses for five incremental stores and 52 thousand square feet of indoor cultivation space in Pennsylvania,” said Charlie Bachtell, Cresco Labs’ CEO & Co-founder. “The moves we’re making in this state to increase our retail footprint and add cultivation put us in the best position to remain the number one wholesaler in the current framework and continue to win when adult-use is ultimately introduced. Another example of our focus on strategic breadth, depth and execution as the path to success today and as this industry evolves.”

The Company expects to transition all stores in Pennsylvania to Sunnyside* by the end of Q1 2022.

About Cresco Labs Inc.

Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

Media:

Jason Erkes, Cresco Labs

Chief Communications Officer

press@crescolabs.com

Investors:

investors@crescolabs.com

For general Cresco Labs inquiries:

312-929-0993

info@crescolabs.com

Source: Cresco Labs Inc.

FAQ

What is the significance of Cresco Labs' acquisition of Cure Pennsylvania?

The acquisition significantly expands Cresco Labs' operational footprint in Pennsylvania, adding three dispensaries to its existing locations.

How will the acquisition impact Cresco Labs' revenue?

Cresco Labs expects to enhance revenues through improved operational efficiencies using its Sunnyside retail model.

When was the acquisition of Cure Pennsylvania completed?

The acquisition was officially closed as announced in the recent press release.

What are the locations of the dispensaries acquired by Cresco Labs?

The acquired dispensaries are located in Lancaster, Phoenixville, and Philadelphia, Pennsylvania.

What is Cresco Labs' strategy for the Pennsylvania market post-acquisition?

Cresco Labs aims to tailor its strategy to the state's dynamics to maintain market dominance and increase profitability.

CRESCO LABS INC

OTC:CRLBF

CRLBF Rankings

CRLBF Latest News

CRLBF Stock Data

374.59M
271.34M
0.66%
5.5%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Chicago